Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZYNE
  • CUSIP: N/A
  • Web: www.zynerba.com
Capitalization:
  • Market Cap: $83.52 million
  • Outstanding Shares: 13,257,000
Average Prices:
  • 50 Day Moving Avg: $6.28
  • 200 Day Moving Avg: $6.28
  • 52 Week Range: $6.10 - $23.57
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.80
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.37 per share
  • Price / Book: 1.19
Profitability:
  • EBIDTA: ($28,660,000.00)
  • Return on Equity: -54.35%
  • Return on Assets: -48.11%
Debt:
  • Current Ratio: 9.73%
  • Quick Ratio: 9.73%
Misc:
  • Average Volume: 314,757 shs.
  • Beta: 5.33
  • Short Ratio: 5.78
 

Frequently Asked Questions for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.04. View Zynerba Pharmaceuticals' Earnings History.

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?

9 brokers have issued twelve-month price targets for Zynerba Pharmaceuticals' stock. Their predictions range from $4.00 to $32.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $11.13 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

What are analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (8/10/2017)
  • 2. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totalling 2,265,898 shares, a drop of 25.0% from the August 15th total of 3,020,759 shares. Based on an average daily trading volume, of 613,139 shares, the short-interest ratio is currently 3.7 days. Currently, 21.5% of the shares of the company are short sold.

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:

  • Armando Anido, Chairman of the Board, Chief Executive Officer
  • Terri B. Sebree, President
  • James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development
  • Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources
  • William Roberts, Vice President - Investor Relations and Corporate Communications
  • Ray Mannion, Vice President - Manufacturing
  • Brian Rosenberger, Vice President - Commercial
  • Warren D. Cooper M.D., Lead Independent Director
  • William J. Federici, Independent Director
  • Thomas L. Harrison, Independent Director

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who owns Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.61%), Marshall Wace North America L.P. (2.96%), JPMorgan Chase & Co. (2.46%), Citigroup Inc. (1.67%), State Street Corp (1.20%) and Pennsylvania Trust Co (1.05%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Who sold Zynerba Pharmaceuticals stock? Who is selling Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bluestein R H & Co., GSA Capital Partners LLP and FNY Managed Accounts LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Citigroup Inc., State Street Corp, Pennsylvania Trust Co, Northern Trust Corp, Vanguard Group Inc., Granite Point Capital Management L.P. and Virtu KCG Holdings LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $6.38.


MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  312
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $11.13 (74.37% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/18/2017Canaccord GenuitySet Price TargetBuy$35.00 -> $9.00LowView Rating Details
8/15/2017CIBCReiterated RatingOutperform -> Market PerformLowView Rating Details
8/15/2017Roth CapitalUpgradeNeutral -> Buy$15.00LowView Rating Details
8/15/2017HC WainwrightSet Price TargetHold$7.00LowView Rating Details
8/15/2017Jefferies Group LLCDowngradeBuy -> Hold$12.00 -> $7.00LowView Rating Details
8/14/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformLowView Rating Details
8/14/2017Cantor FitzgeraldSet Price TargetHold$4.00HighView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
8/7/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$42.00 -> $7.00HighView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings History by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.55)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
2017 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.50)($0.56)
Q2 20173($0.62)($0.51)($0.57)
Q3 20173($0.64)($0.42)($0.56)
Q4 20173($0.66)($0.45)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 34.32%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.00View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.00View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.00View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in Zynerba Pharmaceuticals, Inc. (ZYNE) Declines By 25.0%
www.americanbankingnews.com - September 17 at 1:20 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 16 at 4:54 PM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - September 14 at 2:22 AM
globenewswire.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 3:19 PM
finance.yahoo.com logoZynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 6 at 3:19 PM
benzinga.com logoNemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry - Benzinga
www.benzinga.com - September 5 at 3:40 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded at ValuEngine
www.americanbankingnews.com - September 1 at 10:14 PM
finance.yahoo.com logo2 Marijuana Stocks That Have Imploded Since August Began
finance.yahoo.com - August 23 at 2:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 4:36 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price Target
www.americanbankingnews.com - August 18 at 3:14 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Forecasted to Post FY2019 Earnings of ($1.59) Per Share
www.americanbankingnews.com - August 17 at 3:38 PM
americanbankingnews.com logoJefferies Group LLC Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Hold
www.americanbankingnews.com - August 15 at 8:02 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 15 at 6:40 PM
rttnews.com logoZynerba Pharmaceuticals Inc. (ZYNE) Has Tumbled To A New Low On Study Results
www.rttnews.com - August 15 at 4:16 PM
finance.yahoo.com logoZynerba Midstage Cannabinoid Trial Falls Short
finance.yahoo.com - August 15 at 4:16 PM
americanbankingnews.com logoZynerba Pharmaceuticals' (ZYNE) "Market Perform" Rating Reiterated at CIBC
www.americanbankingnews.com - August 15 at 2:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" by Roth Capital
www.americanbankingnews.com - August 15 at 1:06 PM
globenewswire.com logoZynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ... - GlobeNewswire (press release)
globenewswire.com - August 15 at 8:42 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) PT Set at $4.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 14 at 1:06 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Rating Reiterated by Maxim Group
www.americanbankingnews.com - August 14 at 1:06 PM
finance.yahoo.com logoZynerba Pharmaceuticals Upcoming Catalysts and Price Targets
finance.yahoo.com - August 14 at 8:42 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Zynerba Pharmaceuticals (ZYNE) Stock?
finance.yahoo.com - August 11 at 9:26 AM
finance.yahoo.com logoPharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
finance.yahoo.com - August 11 at 9:26 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 10 at 2:39 PM
americanbankingnews.com logoCantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 12:10 PM
americanbankingnews.com logoJefferies Group Research Analysts Reduce Earnings Estimates for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 12:10 PM
americanbankingnews.com logoZynerba Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ZYNE)
www.americanbankingnews.com - August 10 at 8:06 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - August 9 at 9:44 PM
benzinga.com logoIs GW Pharma Now The Future Of Cannabis-Based Drugs? - Benzinga
www.benzinga.com - August 9 at 8:37 PM
nasdaq.com logoZynerba Pharmaceuticals Inc. (ZYNE) Is Sinking After Phase 2 Study Fails
www.nasdaq.com - August 9 at 9:31 AM
americanbankingnews.com logoOppenheimer Holdings Weighs in on Zynerba Pharmaceuticals, Inc.'s Q3 2017 Earnings (ZYNE)
www.americanbankingnews.com - August 9 at 7:26 AM
americanbankingnews.com logoCantor Fitzgerald Reiterates Overweight Rating for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - August 8 at 8:56 PM
americanbankingnews.com logoRoth Capital Downgrades Zynerba Pharmaceuticals, Inc. (ZYNE) to Hold
www.americanbankingnews.com - August 8 at 1:20 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Eros, Myokardia, Intrepid ... - Nasdaq
www.nasdaq.com - August 8 at 8:35 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (ZYNE) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - August 7 at 10:36 PM
americanbankingnews.com logoOppenheimer Holdings, Inc. Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $8.00 Price Target
www.americanbankingnews.com - August 7 at 6:20 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - August 7 at 2:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Downgraded by Piper Jaffray Companies
www.americanbankingnews.com - August 7 at 12:34 PM
americanbankingnews.com logoCantor Fitzgerald Lowers Zynerba Pharmaceuticals, Inc. (ZYNE) to Neutral
www.americanbankingnews.com - August 7 at 12:32 PM
nasdaq.com logoPre-Market Most Active for Aug 7, 2017 : NXTM, ERIC, TEVA, ZYNE, HZNP, MYL, QQQ, SNAP, BAC, AKS, BABA, CLF - Nasdaq
www.nasdaq.com - August 7 at 8:52 AM
benzinga.com logoA Peek Into The Markets: US Stock Futures Up Ahead Of Fed Speakers - Benzinga
www.benzinga.com - August 7 at 8:52 AM
marketwatch.com logoZynerba Pharma shares plummet 53% on failed trial for cannabidiol gel in epilepsy - MarketWatch
www.marketwatch.com - August 7 at 8:52 AM
finance.yahoo.com logoZynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures
finance.yahoo.com - August 7 at 8:52 AM
finance.yahoo.com logoZynerba's cannabis-based gel for epilepsy fails study
finance.yahoo.com - August 7 at 8:52 AM
finance.yahoo.com logoZynerba's cannabis-based epilepsy gel fails study, shares plunge
finance.yahoo.com - August 7 at 8:52 AM
finance.yahoo.com logoZynerba Pharma shares plummet 53% on failed trial for cannabidiol gel in epilepsy
finance.yahoo.com - August 7 at 8:52 AM
investorplace.com logo3 Stocks to Watch on Monday: Alphabet Inc (GOOGL), Zynerba Pharmaceuticals Inc (ZYNE) and Sony Corp (ADR) (SNE)
investorplace.com - August 7 at 8:43 AM
americanbankingnews.com logo Analysts Expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Will Post Quarterly Sales of $290,000.00
www.americanbankingnews.com - August 5 at 7:09 AM
americanbankingnews.com logoZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - August 4 at 9:08 AM
americanbankingnews.com logo Brokerages Anticipate Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to Post -$0.58 EPS
www.americanbankingnews.com - August 3 at 2:20 PM

Social

Chart

Zynerba Pharmaceuticals (ZYNE) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff